Abbott announced that its pivotal clinical trial of the company's Tecnis® Symfony 1-Piece Acrylic Intraocular Lens (IOL) met its primary endpoint of improved intermediate vision. Data from this study showed that people who received the Tecnis Symfony lens achieved significantly improved intermediate, as well as near, vision compared to those who received a monofocal IOL. The data were presented at the American Society of Cataract and Refractive Surgery (ASCRS) in New Orleans by Jason Jones, M.D., Jones Eye Clinic, Sioux City, Iowa.
"The data from this study showed that patients who received the Symfony lens were more likely to achieve improved intermediate and near vision, while maintaining similar distance vision compared with patients who received a standard IOL." said Dr. Jones, an investigator on the study.
A cataract is a condition in which the lens inside the eye becomes cloudy. Many patients notice the symptoms of a cataract as cloudy or blurred vision, faded color patterns, poor night vision, doubling of images or frequent need to change their glasses prescription. Cataract surgery is one of the safest and most common surgeries performed by eye surgeons, with almost 4 million surgeries performed in the U.S. every year.
The Symfony IOL has been widely studied, with data from more than seven studies in over 2,000 eyes being collected. The Symfony IOL is approved in more than 50 countries around the world. In the U.S., it is an investigational lens and is not available for commercial use.
"The existing Tecnis family of IOLs offers personalized options for patients. The Symfony data presented at ASCRS will be used to support our regulatory application for the lens in the U.S., potentially providing even more choices to doctors and patients." said Thomas Frinzi, senior vice president of Abbott's vision business.
.png)
